Future directions for cardiovascular disease comparative effectiveness research: report of a workshop sponsored by the National Heart, Lung, and Blood Institute.
Comparative effectiveness research (CER) aims to provide decision makers with the evidence needed to evaluate the benefits and harms of alternative clinical management strategies. CER has become a national priority, with considerable new research funding allocated. Cardiovascular disease is a priority area for CER. This workshop report provides an overview of CER methods, with an emphasis on practical clinical trials and observational treatment comparisons. The report also details recommendations to the National Heart, Lung, and Blood Institute for a new framework for evidence development to foster cardiovascular CER, and specific studies to address 8 clinical issues identified by the Institute of Medicine as high priorities for cardiovascular CER.
Stanford University School of Medicine, Stanford, California 94305-5405, USA. hlatky@stanford.edu
Mark A
MA
Hlatky
Pamela S
PS
Douglas
Nakela L
NL
Cook
Barbara
B
Wells
Emelia J
EJ
Benjamin
Kay
K
Dickersin
David C
DC
Goff
Alan T
AT
Hirsch
Elaine M
EM
Hylek
Eric D
ED
Peterson
Véronique L
VL
Roger
Joseph V
JV
Selby
James E
JE
Udelson
Michael S
MS
Lauer
D002318:Cardiovascular Diseases / Q000628:therapy*; D057186:Comparative Effectiveness Research; D019317:Evidence-Based Medicine; D006801:Humans; D015969:National Academies of Science, Engineering, and Medicine, U.S., Health and Medicine Division; D054555:National Heart, Lung, and Blood Institute (U.S.); D017063:Outcome Assessment, Health Care; D016032:Randomized Controlled Trials as Topic; D014481:United States